Product

Further Information
The compound has a long duration of action, potentially reducing the amount of analgesic required for effective pain control. Owing to its unique receptor profile, BTG6001 also has the potential to show a superior side-effect profile compared with current opiate analgesics. BTG plans to complete preclinical development and initiate Phase I clinical studies in the next 12 to 15 months

Currently the first line treatment for post operative pain is morphine and this remains the gold standard. Morphine is short acting and has significant side-effects, the most troublesome of which are constipation, respiratory depression, nausea and vomiting. Although other opiate formulations have been developed with improved profiles, none adequately address the fundamental safety issue of respiratory depression. It is anticipated that the unique receptor profile of BTG6001 will allow for effective analgesia devoid of troublesome side-effects associated with opiates.